Zanubrutinib is a Selective and Orally Active Btk Inhibitor for Leukemia and Lymphoma Research
As we know, Bruton tyrosine kinase (Btk) is a member of the TEC family kinases. In addition, it is involved in B-cell antigen receptor (BCR)-signaling pathway. Usually, BTK is expressed…